Makers Laboratories Q1FY27 profit up 244% to ₹1.50 cr

Key takeaway from the June 2026 quarter

Makers Laboratories Limited reported a sharp improvement in consolidated profitability for Q1FY27, even as its standalone pharmaceutical business remained loss-making. The company said consolidated net profit attributable to owners of the parent rose to ₹1.50 crore for the quarter ended June 30, 2026, from ₹0.44 crore in Q1FY26. Consolidated revenue from operations increased to ₹42.77 crore, compared with ₹35.00 crore a year ago. The results were approved by the Board of Directors at a meeting held on August 7, 2026 in Mumbai.

The update also included a board-level change, with Saahil Parikh set to move from Whole-time Director and CEO to a non-executive role from August 11, 2026, subject to shareholder approval. Alongside the financial disclosures, the company reiterated compliance steps such as trading window restrictions for insiders tied to the results process.

Consolidated financial performance: revenue and income

For Q1FY27, Makers Laboratories reported consolidated revenue from operations of ₹42.77 crore, up from ₹35.00 crore in Q1FY26 and higher than ₹35.75 crore in Q4FY26. Total consolidated income for the quarter stood at ₹43.38 crore.

Profit before tax (PBT) for Q1FY27 was ₹6.29 crore, compared with ₹4.73 crore in Q4FY26 and ₹1.98 crore in Q1FY26. Net profit after tax (before non-controlling interest) was ₹4.60 crore for Q1FY27, versus ₹3.56 crore in Q4FY26 and ₹1.29 crore in Q1FY26. Total comprehensive income was ₹4.62 crore for Q1FY27.

Net profit attributable to owners rises sharply

Net profit attributable to owners of the parent was ₹1.50 crore in Q1FY27, up from ₹0.44 crore in Q1FY26 and ₹1.09 crore in Q4FY26. The company’s disclosure highlighted a strong year-on-year improvement in this profit measure.

Earnings per share (basic and diluted, not annualised) were reported at ₹2.55 in Q1FY27, compared with ₹0.74 in Q1FY26 and ₹1.85 in Q4FY26. The EPS figures were disclosed on a consolidated basis alongside the quarterly results.

Segment view: chemical manufacturing highlighted

The company flagged the Chemical Manufacturing segment as a key contributor during the quarter. It reported segment profit before tax of ₹7.55 crore for Chemical Manufacturing, as part of the discussion on what supported the consolidated performance.

The segment disclosure matters because the broader financials show a divergence between consolidated outcomes and the standalone pharmaceutical business. The company’s quarterly note positioned chemical manufacturing as the stronger-performing segment in the period.

Standalone pharmaceutical business: loss widens

On a standalone basis, Makers Laboratories said the pharmaceutical business reported a net loss of ₹1.08 crore in Q1FY27. This widened from a net loss of ₹0.27 crore in Q1FY26.

Standalone revenue from operations declined to ₹10.19 crore for the quarter, according to the company’s statement. Total standalone income was ₹10.26 crore in Q1FY27. The company characterised the standalone business as continuing to face headwinds during the quarter.

Board decisions and leadership transition

The company said Saahil Parikh (DIN 00400079) informed the Board that he does not wish to be re-appointed as Whole-time Director and CEO after his term concludes on August 10, 2026, citing personal and professional reasons. The Board approved his appointment as a Non-Executive, Non-Independent Director effective August 11, 2026, subject to shareholder approval.

The revised Board composition effective August 11, 2026, as disclosed, includes R. K. P. Verma (Chairman, Independent Director), Dipti Shah (Independent Director), Vishal Jain (Independent Director), Prashant Godha (Non-Executive, Non-Independent Director), Saahil Parikh (Non-Executive, Non-Independent Director), and Nilesh Jain (Executive, Whole-time Director).

Trading window closure and compliance timeline

Makers Laboratories also stated that it closed its trading window for insiders from July 1, 2026. The window is to reopen 48 hours after the declaration of the unaudited financial results for the quarter ended June 30, 2026.

The company said the restriction was implemented to comply with regulatory requirements ahead of its financial results announcement.

Key numbers summary (all ₹ in crore)

The company’s disclosure included the following consolidated quarterly metrics.

Wider context from recent disclosures

For FY26, Makers Laboratories reported a 78.5% decline in consolidated net profit to ₹2.35 crore, despite a 16.4% rise in revenue to ₹140.59 crore, as total expenses increased. On a standalone basis for FY26, the company reported a net loss of ₹1.72 crore, compared with a profit of ₹4.64 crore in the previous year. The company said the Board approved audited standalone and consolidated results for the quarter and year ended March 31, 2026 at a meeting held on May 26, 2026.

Separately, the text also cited full-year FY2026-27 revenue of ₹142.3 crore and profit of ₹7.86 crore.

Market snapshot and what investors will track

The update includes both the improved consolidated profitability in Q1FY27 and the continued loss in the standalone pharmaceutical business, which together shape how investors may read the quarter. It also clarifies the company’s stated reliance on the Chemical Manufacturing segment in the period, based on the segment PBT figure disclosed.

The near-term focus will be on how the company sustains consolidated profitability while addressing the standalone pharma performance. Investors will also track follow-through on the leadership transition effective August 11, 2026, including the shareholder approval process mentioned in the filing. The price reference in the text showed “Today: 143.20”.

Conclusion

Makers Laboratories reported higher Q1FY27 consolidated revenue and a strong rise in profit attributable to owners to ₹1.50 crore, supported by the Chemical Manufacturing segment. At the same time, its standalone pharmaceutical business posted a wider loss, with lower revenue from operations. The company’s Board approved the unaudited results on August 7, 2026, and it disclosed a change in Saahil Parikh’s role effective August 11, 2026, subject to shareholder approval.